Maximus, Inc.
MMS
is currently benefiting from strategic acquisitions and long-term relationships with clients.
The company recently reported first-quarter fiscal 2022 adjusted earnings of $1.12 per share that surpassed the Zacks Consensus Estimate by 40% and increased 8.7% year over year. Revenues of $1.2 billion beat the consensus mark by 5% and increased 21.7% year over year.
How is MMS Doing?
With more than 40 years of experience, Maximus has grown to be a leading operator of government health and human services programs globally. The company’s business process management expertise, and its ability to deliver cost-effective, efficient and high-scale solutions, position it as a lucrative partner to governments. Maximus maintains solid relationships and strong reputation with governments and long-term contracts provide it predictable recurring revenue streams. The company continuously seeks long-term relationships with clients in both existing and adjacent markets. MMS is also focused on expanding its foothold in clinical services, as well as long-term services and supports. Moreover, complex health needs have increased the need for government social benefit and safety-net programs. This should continue driving demand for the company’s services.
Maximus has been active in undertaking acquisitions to expand its business processes, knowledge and client relationships, enhance technical capabilities, and gain additional skill sets. These acquisitions also complement the company’s long-term organic growth strategy. MMS recently purchased the Federal division of Attain. This buyout is expected to strengthen two core pillars of Maximus’ long-term corporate strategy, including accelerating digital transformation and the ongoing expansion into the U.S. federal market.
Maximus’ cash and cash equivalent balance of $182 million at the end of first-quarter fiscal 2022 was well below the long-term debt level of $1.5 billion. The cash level, however, can meet the short-term debt of $79 million.
Zacks Rank and Stocks to Consider
Maximus currently carries a Zacks Rank #1 (Strong Buy). You can see
the complete list of today’s Zacks #1 Rank stocks here
.
Some other stocks in the broader
Business Services
sector that investors may consider are
Cross Country Healthcare
CCRN
,
Accenture
ACN
and
Clean Harbors
CLH
.
Cross Country Healthcare sports a Zacks Rank #1. The company has a long-term earnings growth of 21.5%.
Cross Country Healthcare has a trailing four-quarter earnings surprise of 41.5%, on average. CCRN’s shares have surged 85.5% in the past year.
Accenture carries a Zacks Rank #2 (Buy). The company has an expected earnings growth rate of 19.8% for the current year. The company has a trailing four-quarter earnings surprise of 5.3%, on average.
Accenture’s shares have surged 23.4% in the past year. The company has a long-term earnings growth of 10%.
Clean Harbors carries a Zacks Rank #2. The company has a trailing four-quarter earnings surprise of 43.2%, on average.
CLH’s shares have surged 7.1% in the past year.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report